Prevolac

Quick links to important sections

Prevolac

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prevolac

Quick Facts

Property Description
Active ingredient Azelaic Acid (INN)
Form Topical formulation (cream, gel, or foam)
Pharmacological class Dermatological agent
Common use Anti-acne and anti-rosacea preparation
Origin Synthetic, derived from naturally-occurring dicarboxylic acid

Prevolac is a specialized dermatological agent that is administered as a topical formulation for direct cutaneous application. It is established as a prescription-only medicine whose identity is defined by its function as an anti-acne and anti-rosacea preparation, focusing on localized inflammatory skin conditions. This formulation is clinically recognized for its targeted local efficacy, addressing the underlying pathology of skin conditions.

What Type of Medicine is Prevolac?

Prevolac is classified as a dermatological agent because its action is confined to the skin surface and its underlying structures. As a topical formulation (cream, gel, or foam), the active component is delivered directly to the target tissue, minimizing systemic absorption. This localized delivery method is essential for a drug of this class, often prescribed for the management of persistent papules and pustules.

Composition and Origin: The Role of Azelaic Acid

The sole active component in Prevolac is Azelaic Acid (INN), which is chemically defined as a dicarboxylic acid. The Azelaic Acid utilized is manufactured synthetically to ensure pharmaceutical purity, although it is derived from a compound, nonanedioic acid, that is naturally found in grains such as wheat and barley. This composition is fundamental to the drug’s identity, allowing for targeted delivery and action within the hair follicles.

General Purpose and Mechanism: Correcting Underlying Skin Factors

The general purpose of Prevolac is to correct the pathological factors that contribute to various inflammatory skin conditions. Its unique contribution is derived from its three primary physiological actions: it acts as an antimicrobial agent to reduce the presence of follicle-dwelling bacteria, it functions as an antikeratinizing agent to normalize skin cell growth and prevent pore blockage, and it serves as an anti-inflammatory agent to calm localized redness and swelling. This multifaceted approach provides a comprehensive means of ameliorating the condition of the affected skin.

What side effects are possible with Prevolac?

Possible Side Effects and Safety Information

The safety profile for Prevolac, which contains Azelaic Acid in a topical formulation, is primarily characterized by adverse reactions that occur locally at the application site. These effects are classified according to official regulatory documentation based on frequency.


Frequency of Adverse Reactions

Most common effects are typically confined to the Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions regulatory categories. Systemic adverse events are rare, reflecting the drug's minimal systemic absorption.

Classification Examples of Reactions
Very Common (ge 1/10) Application site burning, pruritus (itching), and erythema (redness).
Common (ge 1/100 to < 1/10) Application site scaling, pain, dryness, and exfoliation.
Rare (ge 1/10,000 to < 1/1,000) Hypersensitivity reactions, facial swelling, urticaria, and worsening of asthma.

Safety Constraints and Time Patterns

The most frequently reported local irritations, such as burning and pruritus, are typically experienced at the beginning of treatment and are officially noted to often subside with continued use.

Regulatory documentation defines certain constraints for use. The formulation is strictly for dermatologic use and must not be allowed to contact the eyes, mouth, or other mucous membranes, as this may cause severe irritation. Hypersensitivity reactions, which include manifestations like angioedema or breathing difficulty, represent the most critical, though rare, safety risk documented in regulatory labels.

Population-specific safety statements note that patients with a dark complexion should be monitored for signs of hypopigmentation (skin lightening). Due to low systemic absorption, exposure to the fetus or via breast milk is generally not expected to be clinically significant.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Prevolac (Azelaic Acid topical) addresses toxicity primarily in the context of accidental exposure and severe localized reactions, owing to its minimal systemic absorption. No specific antidote is documented for systemic overdose in the prescribing information.

Documented Manifestations and Emergency Actions

The most serious acute events requiring immediate attention are severe allergic reactions and accidental ingestion. Manifestations requiring urgent action include new or worsening breathing problems or symptoms consistent with severe hypersensitivity, such as facial swelling or angioedema.

Documented Manifestations Immediate Action Required
Accidental ingestion of the formulation Seek emergency medical attention or call the Poison Help line immediately.
New or worsening breathing problems Stop using the medicine and call a physician at once.
Severe burning, stinging, or redness Stop using the medicine and consult a physician if symptoms persist.
Accidental eye contact Rinse eyes with large amounts of water; consult a physician if irritation persists.

If the product causes severe, persistent irritation or sensitivity, regulatory guidance mandates that treatment must be discontinued and appropriate therapy instituted. Worsening of asthma has been noted in post-marketing reports, a factor relevant during the management of an acute reaction.

Therapeutic Uses of Prevolac

Management of Mild-to-Moderate Acne Lesions

The medication is commonly used to help manage symptoms related to inflammatory or irritative states. It is applied across therapeutic domains where additional symptomatic support is needed for mild-to-moderate acne vulgaris, and is used for managing existing papules and pustules (inflammatory lesions), playing a role in managing precursor lesions like clogged pores and comedones. This contributes to improved day-to-day comfort and supports a reduction in the overall burden of symptoms that interfere with daily functioning.


Relief from Rosacea and Pigmentation Symptoms

Prevolac is also relevant for easing the symptoms of papulopustular rosacea, where patients experience persistent facial redness (erythema) and inflammatory manifestations. It is commonly used in conditions presenting with acute or disruptive symptom patterns, helping to manage symptoms that may become intense or disruptive. Furthermore, the treatment is applied in addressing skin conditions marked by increased physiological stress, specifically the appearance of post-inflammatory hyperpigmentation (PIH) and conditions like melasma.

“The benefit is addressing the visible manifestations of chronic skin conditions, providing supportive relief that helps patients cope more steadily with symptom fluctuations.”

This therapeutic support assists with maintaining functional stability by making episodes of heightened discomfort and persistent discoloration more manageable.

Quick Fact: Relief for Key Symptoms
Main Symptom Axes Inflammatory lesions, facial erythema, and post-inflammatory discoloration.
Common Clinical Context Topical monotherapy or adjunctive support for mild-to-moderate, recurrent conditions.
Symptomatic Benefit Contributes to easing the overall symptom load and supports improved day-to-day comfort.

Regulatory References

  1. NIH MedlinePlus overview on Azelaic Acid

Eligibility and Restrictions for Use

Prevolac (Azelaic Acid Topical) is governed by specific regulatory eligibility rules that define its permitted and prohibited use populations. The medicine is approved for use in Adults for both acne vulgaris and papulopustular rosacea. For the acne indication, eligibility is also established for Adolescents 12 years of age and older.

Absolute Contraindications

Hypersensitivity to the active ingredient, Azelaic Acid, or to any component of the specific formulation (such as propylene glycol in some products) is an absolute prohibition for use, as documented in official prescribing information.


Population Group Official Eligibility Status
Children under 12 Safety and effectiveness have not been established for this age group (acne indication).
Older Adults (65+) Use is not established due to insufficient data in clinical trials.
Pregnancy/Lactation Use is conditional, requiring caution; contact with the treated area must be avoided during nursing.
Hepatic/Renal Impairment No targeted studies have been performed to establish eligibility in patients with liver or kidney impairment.
Dark Complexion Conditional use requiring monitoring for signs of hypopigmentation.

This official profile strictly defines the permitted population and specifies restrictions based on age limitations, known allergies, physiological states, and a lack of clinical data in specific patient groups, such as those with organ impairment, as noted by regulatory agencies.

What should I know about interactions with other medicines?

Interactions with other Medicines and Products

This section summarizes the official regulatory information regarding medicinal product interactions with Prevolac (Lansoprazole).


Contraindicated Combinations

Co-administration of Prevolac with Rilpivirine-containing products is contraindicated. Prevolac significantly raises gastric pH, which substantially reduces the absorption and exposure of Rilpivirine, potentially leading to a loss of therapeutic effect and development of resistance.


Clinically Significant Exposure Modifications

Mechanism Interacting Substances / Categories Interaction Outcome Regulatory Note
Gastric pH Elevation Drugs requiring acidic pH (e.g., Ketoconazole, Iron Salts) Decreased absorption and exposure of the co-administered drug. Requires monitoring or alternative therapy.
CYP Enzyme Effects Fluvoxamine (Inhibitor) Increased exposure ( AUC) of Prevolac. Effect is more pronounced in CYP2C19 poor metabolizers.
Methotrexate Elevated and prolonged serum concentrations of Methotrexate. Caution warranted due to toxicity risk.

Administration Constraints

Prevolac should be administered at least 30 minutes prior to taking Sucralfate. Sucralfate can significantly delay the absorption and reduce the bioavailability of Prevolac, making dose separation necessary for optimal effect.

Some official labels note that co-administration with Clopidogrel is associated with a reduced antiplatelet effect, though the clinical impact varies.

Mechanism of Action

The action of Prevolac is defined by the pleiotropic effects of Azelaic Acid, which engages three primary mechanistic domains at the cellular and molecular level to modulate specific, dysregulated physiological processes.

Modulating Follicular Cell Differentiation

This domain covers the drug's role as an antikeratinizing agent, where it inhibits the DNA and protein synthesis of hyperproliferative keratinocytes in the hair follicle. This mechanism leads to the normalization of follicular epithelial cell turnover and the physical clearance of the follicular canal by inhibiting hyperkeratinization.

Suppressing Microbial Bioenergetics

The antimicrobial mechanism involves Azelaic Acid penetrating follicular bacteria, such as C. acnes, where it non-specifically inhibits oxidoreductase enzymes essential for the mitochondrial respiratory chain. By disrupting the microbes' bioenergetics and protein synthesis, the drug results in the reduction of the local bacterial population and the subsequent lowering of irritant enzyme activity.

Interfering with Inflammatory Cascades

This action relies on the molecule's ability to act as a free radical scavenger by neutralizing Reactive Oxygen Species (ROS) and specifically inhibiting the enzyme Kallikrein-5 ( KLK5). This interference reduces the activation of proinflammatory peptides like cathelicidin, which results in the suppression of localized immune cell activity and the modulation of vascular tone within the skin tissue.

Dosage and Administration Information

Administration Scope

Feature Guideline (Strictly Label-Based)
Route of administration Topical (Cutaneous). It is not for oral, ophthalmic, or intravaginal use.
Dosing schedule Apply a thin layer of the designated strength (15% gel/foam or 20% cream) to the affected area(s).
Preparation requirements The skin must be cleansed using a very mild soap or soapless lotion and pat-dried before application.
Age-group administration rules The 20% cream is approved for acne use in patients 12 years of age and older. Rosacea use is not established in patients under 18 years.
Missed-dose rules Skip the missed dose and continue the regular schedule; a double dose should not be applied.
Special procedural conditions Occlusive dressings or wrappings should be avoided. Hands must be washed immediately following the application.

Instruction Classifications

Classification Pattern
Administration method type Topical (External use only).
Frequency pattern Twice daily (morning and evening). Frequency may be temporarily reduced to once daily if irritation is experienced.
Course duration protocol Reassessment is required if no improvement in rosacea symptoms is observed after 12 weeks of continuous use. For acne, improvement is often seen within 4 weeks.
Use-context constraints Patients are instructed to avoid using alcoholic cleansers, astringents, abrasives, and peeling agents on the treated area.

This procedural structure outlines the precise sequence of steps mandated by regulatory authorities to ensure standardized application of the medicine. The requirements for pre-application cleansing and post-application hand washing establish the necessary hygienic protocol for localized cutaneous use. The instruction to apply a thin layer twice daily defines the standardized dosage and frequency over a defined treatment course, with a specific timeline for reassessment.

Recent Clinical Evidence

Research evidence / Overview of studies for Prevolac

Evidence for Use in Mild-to-Moderate Acne Vulgaris

Research for Azelaic Acid, the active component in Prevolac, primarily uses Randomized Controlled Trials (RCTs). These short-term studies, often lasting around 12 weeks, were used in research exploring how symptoms are measured for change over time. The studies monitored outcomes related to inflammatory lesion counts (papules and pustules) and non-inflammatory lesion counts (blackheads and whiteheads), and used various assessment scales to measure overall skin appearance.

Studies also compared the agent against an inactive substance (a vehicle or placebo) and in some cases, against other topical agents also studied for acne. The trial data are the basis for evaluation, but long-term outcomes for patients are not fully established. Researchers have conducted some extended studies, lasting up to nine months, but data for certain groups and against the newest comparative treatments remain limited.


Evidence for Use in Papulopustular Rosacea

The evidence for this indication also relies heavily on Randomized Controlled Trials (RCTs). Research explored the study parameters related to inflammatory or irritative states, including the number of inflammatory lesions and the measurable severity of persistent facial redness (erythema). Studies monitored responses over defined time intervals, typically with the primary evaluation occurring at around 12 weeks.

Findings describe how the measured parameters evolved in the observed populations when compared to the vehicle used in the trials. The research describes the percentage of participants who achieved a score of 'clear' or 'minimal' disease severity on a global assessment scale. Research for this condition has typically not included patients with other forms, such as phymatous or ocular rosacea.


What Remains Uncertain About Prevolac Research

While many high-quality RCTs exist, a key limitation is that the follow-up durations were limited in many primary efficacy studies, meaning long-term effects are not fully established. Another noted limitation is the statistical variability reported in systematic reviews that pool data from many different trials. This means that while overall trends are described, the findings were mixed across specific individual studies, and comparative evidence against the newest therapeutic options is still developing.

Frequently Asked Questions (FAQ)

Common questions about Prevolac (FAQ)


Q: Is Prevolac safe to take if I already take a vitamin supplement?

Official regulatory information does not detail specific known interactions between the active ingredient, Azelaic Acid, and common vitamin or mineral supplements. Because potential interactions are not explicitly listed, regulatory agencies advise disclosing all supplements and other non-prescription products to a healthcare provider.


Q: Can Prevolac be used by people who have existing liver issues?

Official documentation notes that no dedicated studies have been conducted to establish the eligibility or appropriate use of Prevolac in patients with pre-existing hepatic (liver) or renal (kidney) impairment. This means the required clinical data for these specific populations is currently unavailable in regulatory files.


Q: What should I be aware of regarding Prevolac and UV exposure or sunlight?

Regulatory documentation notes photosensitivity as a potential effect related to the medicine. For this reason, official patient guidance recommends minimizing exposure to direct sunlight and consistently using sun protection on the treated skin areas.


Q: Are there any known interactions between Prevolac and alcohol?

Official patient guidance for the topical gel formulation advises avoiding the consumption of alcoholic beverages while using the product. Furthermore, patients are generally advised to avoid using alcoholic cleansers on the treated area.


Q: Is Prevolac safe to use during pregnancy, according to official guidelines?

The use of Prevolac during pregnancy is described in official documentation as conditional, often requiring caution. Available data suggests the risk to the fetus is generally not expected to be clinically significant due to the drug’s nature as a topical application with low systemic absorption.


Q: Is Prevolac addictive?

Prevolac is not classified as a controlled substance by regulatory agencies in the United States or other major health bodies. Consequently, official documents do not describe any potential for abuse or dependency associated with its use.


Q: Is Prevolac the same kind of medicine as [similar drug name]?

The active component in Prevolac, Azelaic Acid, is classified as a dicarboxylic acid within the family of topical dermatological agents. Official sources may list other agents, such as metronidazole or benzoyl peroxide, as related treatments for acne or rosacea, but they are different chemical classes.


Q: How quickly can someone generally expect Prevolac to start working?

Clinical trial data indicates that for the acne indication, patients often begin to see measurable improvement within 4 weeks of continuous use. For rosacea, continued use for at least 12 weeks is typically required before a significant assessment of symptom change is made.


Q: Can Prevolac cause long-term side effects that I should know about?

Official safety documentation notes that the most frequent local irritations typically subside with continued use. However, patients with a dark complexion are advised to be monitored for signs of hypopigmentation (skin lightening), which is a potential safety concern noted in the context of long-term use.


Q: Does Prevolac have any dietary restrictions associated with it?

Official patient guidance for the topical gel formulation advises avoiding certain food triggers while using the product. This includes avoiding spicy or thermally hot foods and drinks, as these may contribute to the irritation or flushing symptoms associated with the condition being treated.


Q: Is there a generic version of Prevolac available?

Regulatory agencies have approved generic formulations of the active ingredient, Azelaic Acid, for certain strengths and dosage forms, such as the 15% gel. The availability of specific generic versions can vary depending on the particular formulation and the local market.


Q: Will Prevolac make me feel sleepy or tired?

Regulatory safety documentation does not list tiredness, sleepiness, or significant fatigue as known or frequently reported side effects. This finding is consistent with the product’s nature as a topical application, which leads to only minimal systemic absorption.


Q: What is the difference between Prevolac and a supplement for the same condition?

Prevolac is classified as a prescription-only medicine that contains an approved, therapeutically effective concentration of the active ingredient. This classification means it is subject to the full regulatory review and approval process, which is distinct from non-regulated supplements.


Q: How long does Prevolac usually stay in your system after taking it?

Due to the medicine being applied topically, only small amounts of the active ingredient are absorbed into the bloodstream. The biological half-life—the time it takes for half the absorbed drug to be eliminated—is approximately 12 hours.


Q: Is it normal to feel [mild, common side effect] when starting Prevolac?

Official safety documentation indicates that the most common local skin reactions, such as burning, stinging, and itching, are frequently experienced when treatment is first initiated. Official documentation describes these common local reactions as often subsiding or improving with continued use.


Q: Does Prevolac affect birth control effectiveness?

Official drug interaction summaries for Prevolac do not list any known interaction that would alter the effectiveness of hormonal birth control (contraceptives). This absence of a listed interaction is based on the limited systemic absorption of the topical active ingredient.


Q: Are there any warnings about driving or operating machinery while taking Prevolac?

Because Prevolac is a topical application with minimal systemic absorption, the official regulatory documents do not include specific warnings or precautions regarding the ability to drive or operate machinery.


Q: Is it possible to develop a tolerance to Prevolac over time?

Studies examining the antimicrobial effects of the active ingredient, Azelaic Acid, have not identified the development of resistance in C. acnes bacteria. This finding relates to the antimicrobial component of the drug, which is essential for its long-term action.


Q: How is Prevolac typically eliminated from the body?

The small portion of the active ingredient that is systemically absorbed after topical application is primarily metabolized (broken down) in the body. The resulting compounds are then eliminated mainly through the urine.


Q: Does Prevolac interact with any herbal products?

Official regulatory documentation does not list any specific known interactions between the active ingredient, Azelaic Acid, and common herbal products. As with all medications, regulatory agencies advise disclosing all products to a healthcare provider.


Q: I read that Prevolac is sometimes used for [unlisted use]. Is that true?

Official regulatory approval for Prevolac is granted solely for the treatment of mild-to-moderate acne vulgaris and papulopustular rosacea. Any other uses are not approved or described in the official labeling reviewed by regulatory agencies.


Q: Is the mechanism of action of Prevolac fully understood by researchers?

Official research literature indicates that while the active ingredient is known to have multiple actions, the exact, detailed mechanism of action for its full therapeutic effect in conditions like rosacea is not yet fully understood by researchers.


Q: What is the typical timeframe for clinical trials on Prevolac?

The primary efficacy trials used to establish regulatory approval for Prevolac typically utilized short-term study designs. These studies were often conducted over periods lasting around 12 weeks of continuous use before the main assessment was performed.


Q: Does the efficacy of Prevolac depend on the person's age or gender?

Official eligibility rules differentiate use by age, with approval for acne established for patients 12 years of age and older, and rosacea approval established for adults 18 years of age and older. Clinical trials are typically inclusive of all genders.


Q: What is the meaning of the [specific medical term] used in the Prevolac safety documentation?

The official documentation uses technical terms that refer to common skin reactions. For example, Pruritus refers to the sensation of itching, and Erythema refers to redness of the skin at the application site.

How should Prevolac be stored and disposed of?

How to Store and Dispose of Prevolac

This information is based on the official storage and disposal requirements stated in regulatory documentation.

Official Storage Requirements

  • Temperature and Handling: Store Prevolac below 30 C. It is explicitly required not to freeze the product and generally not to refrigerate it, unless specified otherwise for a specific formulation.
  • Packaging Integrity: Keep the medicine in its original outer carton with the container tightly closed to ensure protection from light and moisture, as mandated for product stability.
  • Child Safety: As with all medicines, the product must be kept strictly out of the sight and reach of children.

Stability and Disposal

The label defines the Stability and Shelf-Life Constraints with an expiration date, and may provide specific in-use stability periods after the package is first opened or prepared.

For disposal, the Official Disposal Rules state that unused or expired Prevolac must not be disposed of via household trash or wastewater. Disposal must be performed according to local pharmaceutical take-back programs or waste requirements to ensure environmental safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prevolac found in:

A-Z Index: